Department of Cardiology, APHP, ICAN (Institute of CardioMetabolism and Nutrition), Pitié-Salpêtrière Hospital, ACTION Study group, Paris, France.
Sorbonne University, Paris, France.
ESC Heart Fail. 2024 Jun;11(3):1506-1514. doi: 10.1002/ehf2.14694. Epub 2024 Feb 15.
Inherited cardiomyopathies are relatively rare but carry a high risk of cardiac maternal morbidity and mortality during pregnancy and postpartum. However, data for risk stratification are scarce. The new CARPREG II score improves prediction of prognosis in pregnancies associated with heart disease, though its role in inherited cardiomyopathies is unclear. We aim to describe characteristics and cardiac maternal outcomes in patients with inherited cardiomyopathy during pregnancy, and to evaluate the interest of the CARPREG II risk score in this population.
In this retrospective single-centre study, 90 consecutive pregnancies in 74 patients were included (mean age 32 ± 5 years), including 28 cases of dilated cardiomyopathy (DCM), 46 of hypertrophic cardiomyopathy, 11 of arrhythmogenic right ventricular cardiomyopathy and 5 of left ventricular noncompaction, excluding peripartum cardiomyopathy. The discriminatory power of several risk scores was assessed by the area under the receiver-operating characteristic curve (AUC). Median CARPREG II score was 2 [0;3] and was higher in the DCM subgroup. A severe cardiac maternal complication was observed in 18 (20%) pregnancies, mainly driven by arrhythmia and heart failure (each event in 10 pregnancies), with 3 cardiovascular deaths. Forty-three pregnancies (48%) presented foetal/neonatal complications (18 premature delivery, 3 foetal/neonatal death). CARPREG II was significantly associated with cardiac maternal complications (P < 0.05 for all) and showed a higher AUC (0.782) than CARPREG (0.755), mWHO (0.697) and ZAHARA (0.604).
Pregnancy in women with inherited cardiomyopathy carries a high risk of maternal cardiovascular complications. CARPREG II is the most efficient predictor of cardiovascular complications in this population.
遗传性心肌病较为罕见,但在妊娠和产后期间会使母体患心脏病的风险和死亡率升高。然而,用于风险分层的数据却很少。新的 CARPREG II 评分提高了与心脏病相关妊娠的预后预测,但它在遗传性心肌病中的作用尚不清楚。我们旨在描述妊娠期间遗传性心肌病患者的特征和母体心脏结局,并评估 CARPREG II 风险评分在该人群中的作用。
在这项回顾性单中心研究中,纳入了 74 例患者的 90 例连续妊娠(平均年龄 32±5 岁),包括 28 例扩张型心肌病(DCM)、46 例肥厚型心肌病、11 例致心律失常性右室心肌病和 5 例左室致密化不全,不包括围产期心肌病。通过接受者操作特征曲线(ROC)下面积(AUC)评估了几种风险评分的判别能力。中位 CARPREG II 评分为 2 [0;3],在 DCM 亚组中更高。18 例(20%)妊娠中观察到严重的母体心脏并发症,主要由心律失常和心力衰竭引起(各有 10 例妊娠),有 3 例心血管死亡。43 例(48%)妊娠出现胎儿/新生儿并发症(18 例早产,3 例胎儿/新生儿死亡)。CARPREG II 与母体心脏并发症显著相关(所有 P<0.05),其 AUC(0.782)高于 CARPREG(0.755)、mWHO(0.697)和 ZAHARA(0.604)。
患有遗传性心肌病的女性妊娠存在母体心血管并发症的高风险。CARPREG II 是该人群中预测心血管并发症最有效的指标。